相关临床试验
144
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1451
进行中（未招募）
5
3.5%
已完成
71
49.3%
尚未招募
3
2.1%
招募中
21
14.6%
暂停
4
2.8%
终止
2
1.4%
Unknown
34
23.6%
撤回
4
2.8%
暂无批准数据
- The Sustainable Aquaculture Innovation Cluster (SAIC) has appointed 14 international experts to a new science panel to guide its research and innovation funding decisions. - The panel, chaired by Pieter van West of the University of Aberdeen, spans fish and shellfish health, environmental science, veterinary medicine, seaweed, and technology. - The appointments coincide with SAIC's first full funding call since becoming independent from the University of Stirling, launched on 24 August. - SAIC secured £1.4 million in annual funding for at least five years from Crown Estate Scotland, supporting its relocation to the Highlands.
- A study in the Journal of Cell Biology identifies a previously unknown trafficking pathway by which antisense oligonucleotides (ASOs) enter pancreatic cancer cells and reach their RNA targets. - Researchers found that a KRAS-targeting ASO binds the cell-surface receptor CD44, activating EPHA2 to anchor ASO-containing endosomes near the nucleus, where lipid peroxidation allows escape into the cytoplasm. - Deleting CD44 or EPHA2, or blocking stress granule formation with the drug ISRIB, modulated the ASO's ability to suppress mutant KRAS and inhibit tumor growth. - The findings suggest CD44, highly expressed in aggressive pancreatic cancers, could serve as a "gatekeeper" for delivering therapeutic ASOs to tumors.
- A major 2022 analysis of 76 trials and over 103,000 patients found GLP-1 users were 37 percent more likely to develop gallbladder or bile duct problems. - NHS gallbladder operations reached 80,196 in 2024-25, the highest in a decade and a 15 percent rise year on year, with surgeons reporting weekly GLP-1 cases. - Retatrutide, an unapproved triple-agonist peptide, is being sold illegally online as a 'research chemical' while still in phase 3 trials. - Eli Lilly plans to seek regulatory review of retatrutide in early 2027, but experts warn unregulated supplies carry dosing, purity and infection risks.
- A study of over 91,000 UK Biobank participants found that prolonged, uninterrupted sitting bouts of 30 minutes or more were associated with a 9% higher risk of cancer death per additional hour. - Sedentary time accumulated in shorter, interrupted bouts showed the opposite pattern, with each additional hour linked to an approximately 18–19% lower risk of cancer death. - Replacing one hour of prolonged sitting with light physical activity was associated with a 12% lower cancer death risk, while 30 minutes of moderate activity was linked to an 8% lower risk. - The observational findings suggest that how sedentary time is accumulated—not just total sitting time—may matter for cancer risk, though intervention studies are needed to confirm causality.
- Many patients with rheumatoid arthritis and other immune-mediated inflammatory diseases fail to meet treatment goals despite biologic therapy, giving rise to a "difficult-to-treat" population that requires holistic care. - Psychosocial distress, comorbidities, chronic pain syndromes, and system-related barriers — not just pharmacotherapeutic failure — drive poor outcomes in difficult-to-treat patients, according to viewpoint articles in Nature Reviews Rheumatology and Lancet Rheumatology. - Experts emphasize that rheumatologists must look beyond disease activity scores, incorporating multidisciplinary care, lifestyle medicine, and patient-centered communication to address the full complexity of these cases. - Leading rheumatologists call on organizations like the ACR and EULAR to expand clinical guidelines, fund research into non-pharmacologic therapies, and codify whole-person care models for this underserved population.
- The OPTIMA trial involving over 4,400 patients demonstrated that the Prosigna genomic test can identify hormone receptor-positive breast cancer patients who can safely avoid chemotherapy without compromising outcomes. - Patients with low Prosigna scores showed nearly identical survival rates whether they received chemotherapy or hormone therapy alone, with 93.6% versus 94.8% remaining cancer-free after five years. - The findings could transform treatment decisions for the most common breast cancer subtype, potentially sparing thousands of patients from chemotherapy's severe side effects while reducing healthcare costs. - Researchers believe this represents a major milestone in precision breast oncology, providing Level 1A evidence for genomic-guided treatment decisions in early-stage breast cancer care.
- Moleculent AB closed a $20 million financing round led by Rubicon Healthcare Partners to scale its functional profiling platform that maps cell-cell communication in human tissue. - The technology uses proprietary Proximity Ligation Assay to detect cell interactions in their native environment, addressing a critical gap in understanding how cells communicate within tissues. - Strong demand from research institutions and pharmaceutical partners across Europe and the US has prompted expansion of the company's Techstart Early Access Program. - The funding will accelerate commercial operations in the United States and drive the commercial launch of an automated instrument for large-scale studies.
- The TARTAN-HF trial found that 24.9% of diabetes patients with heart failure risk factors had previously undetected heart failure, compared to just 1% in the control group. - The study tested a simple GP-led screening pathway using NT-proBNP blood testing followed by cardiac ultrasound to identify undiagnosed heart failure in diabetic patients. - The screening approach enabled earlier identification of heart failure and initiation of guideline-directed therapy that could slow disease progression and improve patient outcomes. - Researchers are now analyzing how earlier detection could affect NHS care costs for at-risk diabetes patients.
- A 73-year-old man in Scotland became the world's first patient to receive gene therapy during heart bypass surgery, marking a breakthrough in cardiovascular treatment. - The PROTECT trial delivers TIMP-3 gene therapy directly to vein grafts during surgery to prevent vessel thickening and blockages that commonly cause bypass failure. - The innovative ex vivo treatment approach uses viral vectors to strengthen grafted vessels before implantation, potentially extending bypass durability beyond current standards. - This pioneering study represents over 20 years of translational research and opens new possibilities for gene therapy applications in cardiovascular medicine.
- Tirzepatide demonstrated similar cardiovascular benefits to dulaglutide in patients with type 2 diabetes, regardless of whether they had a history of heart failure. - The drug showed superior outcomes for all-cause death and heart failure hospitalizations compared to dulaglutide in both patient groups with and without heart failure. - Results from the SURPASS-CVOT trial suggest tirzepatide's cardiovascular protective effects are consistent across different heart failure populations. - The study included 13,165 participants with type 2 diabetes and atherosclerotic cardiovascular disease followed for a median of 4 years.
